141 related articles for article (PubMed ID: 2780671)
1. Retroperitoneal lymph node dissection (RPLND) post chemotherapy for non-seminomatous testicular neoplasms: what is the significance of residual masses at scanner control after chemotherapy and should they be removed?
Solé-Balcells F; Villavicencio H; Germá R
Prog Clin Biol Res; 1989; 303():759-62. PubMed ID: 2780671
[No Abstract] [Full Text] [Related]
2. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
3. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
4. Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors of the testis.
Jacqmin D
Eur Urol; 2008 Feb; 53(2):272-3. PubMed ID: 18045771
[No Abstract] [Full Text] [Related]
5. Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer tumors of the testis.
Culine S
Eur Urol; 2008 Feb; 53(2):273-4. PubMed ID: 18045772
[No Abstract] [Full Text] [Related]
6. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
Williams SB; Kacker R; Steele GS; Richie JP
Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
[TBL] [Abstract][Full Text] [Related]
7. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
8. Value of retroperitoneal lymphadenectomy after chemotherapy for non-seminomatous testicular tumor with lymph node metastases.
Le Guillou M; Ferriere JM; Brucher P; Mettetal PJ
Prog Clin Biol Res; 1989; 303():813. PubMed ID: 2780677
[No Abstract] [Full Text] [Related]
9. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
12. Retroperitoneal lymph node dissection after chemotherapy.
Winter C; Raman JD; Sheinfeld J; Albers P
BJU Int; 2009 Nov; 104(9 Pt B):1404-12. PubMed ID: 19840021
[TBL] [Abstract][Full Text] [Related]
13. The role of retroperitoneal lymph node dissection in the management of testicular cancer.
Stephenson AJ; Sheinfeld J
Urol Oncol; 2004; 22(3):225-33; discussion 234-5. PubMed ID: 15271322
[TBL] [Abstract][Full Text] [Related]
14. [Growing teratoma syndrome].
Urruchi Fernández P; Cavero Rebollo O; Jiménez Mas JA; Martínez Bengoechea J; González Enguita C; Rioja Sanz LA
Actas Urol Esp; 1991; 15(2):205-8. PubMed ID: 1807117
[TBL] [Abstract][Full Text] [Related]
15. Vena cava resection during post chemotherapy lymphadenectomy for testis tumor.
Pantuck AJ; Barone JG; Cummings KB
Am Surg; 1995 May; 61(5):424-6. PubMed ID: 7733548
[TBL] [Abstract][Full Text] [Related]
16. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Koch MO; Wahle GR; Donohue JP
J Urol; 2001 May; 165(5):1517-20. PubMed ID: 11342909
[TBL] [Abstract][Full Text] [Related]
17. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
18. Retroperitoneal lymph node dissection in the treatment of patients with non-seminoma testicular tumours.
Kułakowski A; Dardziński R
Eur J Surg Oncol; 1991 Dec; 17(6):581-4. PubMed ID: 1660411
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
20. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
